Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.51 |
| ▸ | NPC1 | O15118 | 8/20 | 0.51 |
| ▸ | HPGD | P15428 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968899 | 1.00 | RAB9A (0.51) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL406844 | 1.00 | RAB9A (0.51) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL2773888 | 0.89 | MRGPRX4 (0.43) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL2772950 | 0.88 | SMN1; SMN2 (0.47) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL17864554 | 0.88 | HPGD (0.51) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL19583276 | 0.88 | HPGD (0.51) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL19583275 | 0.88 | HPGD (0.51) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL9968909 | 0.88 | SMN1; SMN2 (0.47) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL2772953 | 0.88 | SMN1; SMN2 (0.47) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL6116186 | 0.84 | GAA (0.50) | RAB9ANPC1HPGDSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414342-A1 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | RAB9A 2090/4885NPC1 4814/4885HPGD 1367/4885 |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | RAB9A 4195/4885NPC1 3880/4885HPGD 786/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | RAB9A 4195/4885NPC1 3880/4885HPGD 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.